Telix Pharmaceuticals Limited

OTCPK:TLPP.F Stock Report

Market Cap: US$3.2b

Telix Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:TLPP.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
04 May 26SellUS$9,536,328Challenger LimitedCompany856,223US$11.14
29 Apr 26BuyUS$711,115Christian BehrenbruchIndividual67,935US$10.47
29 Apr 26BuyUS$996,738Christian BehrenbruchIndividual67,935US$14.87
24 Apr 26BuyUS$3,189,320JPMorgan Chase & Co.Company320,713US$10.85
24 Apr 26SellUS$1,351,807JPMorgan Chase & Co.Company125,136US$11.03
15 Apr 26BuyUS$19,384JP Morgan Asset ManagementCompany1,816US$10.67
14 Apr 26BuyUS$6,802,114JPMorgan Chase & Co.Company1,326,566US$11.39
14 Apr 26SellUS$9,588,096JPMorgan Chase & Co.Company2,188,808US$11.26
13 Apr 26SellUS$508,887Challenger LimitedCompany46,000US$11.06
01 Apr 26SellUS$12,757,600Challenger LimitedCompany1,385,977US$9.20
30 Mar 26BuyUS$64,275JP Morgan Asset ManagementCompany8,812US$7.88
25 Mar 26SellUS$19,739JPMorgan Chase & Co.Company2,312US$9.17
20 Mar 26BuyUS$9,006,145Challenger LimitedCompany1,129,501US$7.97
19 Mar 26SellUS$862,861JP Morgan Asset ManagementCompany100,028US$8.78
10 Mar 26BuyUS$9,026,438Challenger LimitedCompany1,153,900US$7.82
05 Mar 26BuyUS$4,131JPMorgan Chase & Co.Company581US$7.11
05 Mar 26SellUS$1,134,776Challenger LimitedCompany158,600US$7.15
17 Feb 26BuyUS$5,329,161JPMorgan Chase & Co.Company846,943US$7.27
17 Feb 26SellUS$1,824,411JPMorgan Chase & Co.Company267,302US$7.34
04 Feb 26BuyUS$7,053,934JPMorgan Chase & Co.Company904,800US$8.31
04 Feb 26SellUS$4,647,697JPMorgan Chase & Co.Company591,278US$8.29
21 Jan 26BuyUS$55,756,999Challenger LimitedCompany5,512,680US$10.11
21 Jan 26BuyUS$3,976,853JPMorgan Chase & Co.Company544,347US$7.51
21 Jan 26SellUS$8,219JPMorgan Chase & Co.Company1,138US$7.22
21 Jan 26SellUS$64,480,948Challenger LimitedCompany7,345,877US$8.78
20 Jan 26BuyUS$3,644JPMorgan Chase & Co.Company474US$7.69
20 Jan 26BuyUS$25,290,206JPMorgan Chase & Co.Company2,902,453US$10.34
20 Jan 26SellUS$244,686JP Morgan Asset ManagementCompany30,266US$9.62
20 Jan 26SellUS$42,478,311JPMorgan Chase & Co.Company4,967,439US$10.34
12 Nov 25BuyUS$110,505,841JPMorgan Chase & Co.Company10,122,238US$16.59
12 Nov 25SellUS$89,202,926JPMorgan Chase & Co.Company8,175,593US$16.59
10 Nov 25SellUS$2,186,872JP Morgan Asset ManagementCompany237,822US$15.58
23 Sep 25BuyUS$17,998,978Challenger LimitedCompany1,675,946US$10.74
23 Sep 25SellUS$1,034,641Challenger LimitedCompany101,000US$10.24
10 Sep 25SellUS$3,913,369Challenger LimitedCompany425,000US$9.21
09 Sep 25BuyUS$2,951,392Challenger LimitedCompany318,741US$9.26
28 Aug 25SellUS$4,681,026Challenger LimitedCompany484,952US$9.65
22 Aug 25BuyUS$2,958,474Challenger LimitedCompany248,014US$11.93
01 Aug 25BuyUS$85,312,827Challenger LimitedCompany5,590,391US$15.26
01 Aug 25SellUS$28,574,700Challenger LimitedCompany2,055,036US$13.90
16 Jul 25BuyUS$58,334JP Morgan Asset ManagementCompany3,710US$15.72

Insider Trading Volume

Insider Buying: TLPP.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of TLPP.F?
Owner TypeNumber of SharesOwnership Percentage
Private Companies4,817,3951.42%
Public Companies10,947,1813.23%
Individual Insiders49,989,44614.7%
General Public117,127,65634.5%
Institutions156,497,15346.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 63.39% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.1%
JPMorgan Chase & Co.
34,399,211US$320.7m33.2%0.04%
8.71%
State Street Global Advisors, Inc.
29,545,769US$275.4m-11.4%0.01%
6.68%
Andreas Kluge
22,675,000US$211.4m0%no data
6.3%
Christian Behrenbruch
21,396,941US$199.5m-1.53%no data
4.98%
Challenger Limited
16,907,315US$157.6m-1.14%5.58%
4.13%
Citigroup Inc.
13,999,919US$130.5m23.6%0.06%
3.23%
Grand Pharmaceutical Group Limited
10,947,181US$102.0m0%no data
2.27%
Australian Super Pty Ltd
7,687,939US$71.7m0%0.05%
2.13%
Vanguard Capital Management, LLC
7,223,012US$67.3m0.33%no data
1.89%
Norges Bank Investment Management
6,429,128US$59.9m0%no data
1.81%
Vanguard Investments Australia Limited
6,148,173US$57.3m1.7%0.05%
1.79%
BlackRock, Inc.
6,071,278US$56.6m0.41%no data
1.44%
UV-Cap GmbH & Co KG
4,878,261US$45.5m-10.1%no data
1.28%
RBC Global Asset Management Inc.
4,340,294US$40.5m-0.44%0.02%
1.07%
Mark Nelson
3,628,750US$33.8m0%no data
0.74%
Oncidium Foundation
2,513,616US$23.4m0%no data
0.71%
Netwealth Investments Ltd.
2,406,576US$22.4m19.7%0.19%
0.65%
Vanguard Fiduciary Trust Company
2,195,416US$20.5m0.11%no data
0.58%
Sanlam Investments Uk Limited
1,959,548US$18.3m0%0.58%
0.57%
Lightpoint Medical Ltd
1,918,112US$17.9m0%no data
0.56%
BetaShares Capital Limited
1,905,361US$17.8m1.6%0.06%
0.52%
Yelwac Pty Ltd
1,762,500US$16.4m0%no data
0.5%
Dimensional Fund Advisors LP
1,708,504US$15.9m0%no data
0.4%
Portland Investment Counsel Inc.
1,362,964US$12.7m0%3.42%
0.33%
Nancris Pty Ltd
1,136,783US$10.6m0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/01 23:52
End of Day Share Price 2026/06/01 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Telix Pharmaceuticals Limited is covered by 21 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Melissa BensonBarrenjoey Markets Pty Limited
John HesterBell Potter
Madeleine WilliamsCanaccord Genuity